Breast cancer is biologically heterogeneous, yet conventional clinical decisions rely on static, single-marker proxies (ER, PR, HER2, and Ki-67) that capture only a narrow slice of tumor biology. This mini-review argues that AI-driven multi-omics biomarkers offer a valuable shift toward systems-level, model-derived pro...
D. Stylianakis, R. Sánchez-Bayona, N. Denaro et al.· Frontiers in Pharmacology· 0 citations
The characteristics of the FDA-approved and other investigational IDH-targeted drugs are described, evaluating the most recent clinical studies on targeting IDH genomic alterations in the treatment of gliomas and cholangiocarcinoma.
Virginia Agnetti, Alessandro Acunzo, Giulia Airò et al.· Discover medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.